IPO Profile: Steadymed Ltd

Company Details

San Ramon, Calif.

925-361-0050

www.steadymed.com

Description: SteadyMed Ltd. is a pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of products in certain orphan and other specialty markets. The company’s lead candidate is Trevyent, a development-stage drug product that utilizes SteadyMed’s PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump offers a solution for delivering a range of drug products with volumes greater than two milliliter. In addition, the company offers two product candidates for the treatment of post-surgical and acute pain in the home setting: bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. These two products are referred as At Home Patient Analgesia (AHPA) products. The company has offices in San Ramon, Calif., and Rehovot, Israel.

IPO Details

Exchange and Ticker: Nasdaq: STDY

Filing Range: 4.25 million shares @ $12.00 to $14.00

Offering Price: $8.50

Offering Size: $40 million

Shares Outstanding: 12.7 million

Underwriters: Wells Fargo Securities LLC, RBC Capital Markets

Company Counsel: Cooley LLP

Manager Counsel: Torys

Auditor: Kost Forer Gabbay & Kasierer

Market Capitalization on 3/31/15: $107.92 million

Close price on 3/31/15: $8.5

Investment Details

Venture Backers:

• Deerfield Management Company LP
• Undisclosed Firm
• Federated Investors Inc
• Samson Venture Partners LLC
• KB Partners LLC

Financing Rounds:

• 9/17/12 $10.4M
• 1/29/15 $12.2M

Source: Data provided by Thomson Reuters.